Introduction to Real-World Evidence

Understanding NSAID safety in osteoarthritis is essential for effective clinical management. While non-steroidal anti-inflammatory drugs (NSAIDs) remain a therapeutic cornerstone for osteoarthritis (OA), clinical trials often exclude complex patient profiles. Consequently, real-world data provides a more comprehensive view of how these drugs perform in the general population. A recent large-scale study analyzed twenty years of data from the FDA Adverse Event Reporting System (FAERS). This investigation revealed both expected and surprising adverse events (AEs) across various commonly used NSAIDs.

Detailed Findings on NSAID Safety in Osteoarthritis

Researchers examined Ibuprofen, Naproxen, Diclofenac, Celecoxib, Rofecoxib, and Piroxicam. Beyond the typical gastrointestinal and renal concerns, specific drug-event associations emerged. For instance, reports linked Ibuprofen use in OA patients with anemia and dyspepsia. Notably, Naproxen was associated with inappropriate antidiuretic hormone secretion (SIADH) and respiratory failure. Furthermore, Diclofenac showed signals for sciatica, glossodynia (tongue pain), and gastric ulcers.

Cyclooxygenase-2 (COX-2) inhibitors also displayed distinct profiles. Celecoxib was associated with ischemic stroke, facial edema, and toxic skin eruptions. Although Rofecoxib is largely withdrawn, the data confirmed its links to cerebrovascular accidents and depression. Additionally, Piroxicam users reported cases of alveolitis and erythema multiforme. These findings suggest that clinicians must monitor a broader range of systemic disorders than previously emphasized.

Temporal Patterns and Risk Assessment

The study utilized Time-to-Onset (TTO) analysis to evaluate when these events typically occur. Specifically, Diclofenac-associated gastric ulcers and Ibuprofen-associated dyspepsia followed an \"early-failure\" model. This means these events often occur shortly after starting the medication. Conversely, most other drug-event combinations followed a \"random-failure\" model, occurring at various points during treatment. Therefore, long-term vigilance remains necessary regardless of how long a patient has tolerated the drug.

Clinical Implications for Doctors in India

In India, where NSAIDs are frequently available over-the-counter, these signals are particularly relevant. Physicians should consider these specific risks when tailoring OA treatment. For example, monitoring for respiratory issues with Naproxen or hematological changes with Ibuprofen could improve patient safety. Ultimately, this pharmacovigilance perspective complements evidence from controlled trials to guide safer prescribing habits.

Frequently Asked Questions

What are the unexpected side effects of Celecoxib identified in this study?

In addition to cardiovascular risks, this study identified associations between Celecoxib and ischemic stroke, facial edema, cerebrovascular disorders, and toxic skin eruptions in OA patients.

Which NSAIDs were most closely linked to early-onset gastrointestinal issues?

Diclofenac was strongly associated with gastric ulcers, and Ibuprofen was linked to dyspepsia. Both followed an early-failure model, meaning they often manifest early in the course of treatment.

How does this study change the understanding of Naproxen safety?

Beyond common side effects, this study highlighted rarer but serious associations with Naproxen, including respiratory failure and inappropriate antidiuretic hormone secretion (SIADH).

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional recommendation. Clinicians should use their professional judgment and refer to the latest local and national guidelines for clinical practice.

References

1. Zhang K et al. Evaluating adverse events reported for non-steroidal anti-inflammatory drugs in osteoarthritis: a real-world pharmacovigilance study. Inflammopharmacology. 2026 Feb 09. doi: 10.1007/s10787-026-02129-1. PMID: 41656471.

2. Solomon DH, et al. The Risk of Major NSAID Toxicity with Celecoxib, Ibuprofen, or Naproxen: A Secondary Analysis of the PRECISION Trial. Am J Med. 2017 Dec;130(12):1415-1422.e4.

3. Indian Orthopaedic Rheumatology Association (IORA). Position statement on the pharmacological management of osteoarthritis. 2025.